Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04679909 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A Phase 1 study, sponsored by Altimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT04679909 is a Phase 1 study that has completed, run by Altimmune. The registered enrollment target is 92 participants.
The verdict
NCT04679909, a Phase 1 study, has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
Interventions
- OTHER Placebo
- BIOLOGICAL AdCOVID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04679909
The ClinicalTrials.gov registry entry for NCT04679909 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altimmune, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04679909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04679909 about?
NCT04679909 is a clinical study titled "Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)". A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
What is the current status of trial NCT04679909?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2021-02-25. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT04679909?
The interventions under investigation include: Placebo (OTHER), AdCOVID (BIOLOGICAL).
Who is sponsoring clinical trial NCT04679909?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.